Tuesday, 28 June 2022


Korea to run training programme on vaccines and biologics development

17 February 2022 | News

IVI named operator of ‘2022 Global Bio-Intensive Training Courses’ by Korean Ministry of Health and Welfare

image credit- shutterstock

image credit- shutterstock

The International Vaccine Institute (IVI) has been designated by the Ministry of Health and Welfare (MOHW), Republic of Korea as the operator of 2022 Global Bio-Intensive Training Courses’ to provide workforce training in vaccine and biologics R&D and manufacturing for students from low- and middle-income countries (LMICs) and Korea.

The training courses, the first of its kind global programme supported by the Government of Korea, aim to provide essential, practical knowledge through an intensive short-term program designed to strengthen students’ professional capacity.

Accordingly, the new programme will include offline and online courses on biologics development and manufacturing and on standard practice (GxP), plus onsite training and consultation.

Funded with a KRW4.3 billion won ($3.6 million) grant from MOHW, the programme will provide 450 trainees (including 300 from LMICs) with comprehensive education designed to equip them with necessary skills in the development and production of biopharmaceuticals. Online courses will also be made available to additional trainees.

IVI will help trainees gain and deepen practical knowledge and skills to ensure that they will be prepared to manage development and production processes, biopharmaceutical manufacturing facilities, and biosafety through a mix of professional training courses offline and online. It will also offer customized onsite training and consultation to vaccine and biotechnology companies in LMICs to enable them to produce biopharmaceuticals in compliance with international regulatory standards.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account